Crizotinib

(Xalkori®)

Crizotinib

Drug updated on 11/1/2024

Dosage FormCapsule (oral; 200 mg, 250 mg); pellet (oral; 20 mg, 50 mg, 150 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indiacted for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test
  • Indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive
  • Indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 33 systematic review(s)/meta-analysis(es). [1-33]
  • Lorlatinib: Demonstrates superior progression-free survival (PFS) over crizotinib with hazard ratios (HRs) of 0.61 (95% CrI: 0.39, 0.97) versus alectinib and 0.57 (95% CrI: 0.35, 0.93) versus brigatinib; ranks highest for objective response rate (ORR) among ALK (anaplastic lymphoma kinase) inhibitors.
  • Alectinib: Significantly prolongs PFS in both first-line and second-line settings compared to crizotinib and shows a lower grade 3-4 adverse event rate (16.2%) compared to other ALK inhibitors, making it the safest option in terms of adverse effects.
  • Crizotinib: Shows a median PFS of 14.5 months and a median overall survival (OS) of 40.2 months in ROS1-positive NSCLC real-world settings; notable for a pooled ORR of 70.6% but associated with higher risks of thromboembolism and venous thromboembolism compared to brigatinib and ceritinib.
  • Iruplinalkib: Ranked highest for cumulative PFS benefit (SUCRA (surface under the cumulative ranking curve)) among ALK inhibitors, especially effective in Asian patient populations, with subsequent rankings favoring brigatinib and ensartinib for this subgroup.
  • Lorlatinib: Has a high incidence of grade 3-4 adverse events, occurring in 91.6% of cases, with specific events including cognitive and mood effects, as well as lipid level alterations.
  • Crizotinib: Demonstrates elevated risks for thromboembolism and venous thromboembolism relative to brigatinib and ceritinib, along with gastrointestinal reactions, visual disorders, and elevated liver enzymes.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Xalkori (crizotinib) Prescribing Information.2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)2024Lung Cancer (Amsterdam, Netherlands)
Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis2024Bmj Open
Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naive advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis2024Translational Lung Cancer Research
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence2024Lung Cancer (Amsterdam, Netherlands)
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis2024Bmc Cancer
Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments2023Frontiers In Oncology
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis2023Exploration Of Targeted Anti-Tumor Therapy
Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review2023Cureus
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis2023Lung Cancer (Amsterdam, Netherlands)
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review2023Frontiers In Pharmacology
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer2023Cancer Medicine
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden2023Applied Health Economics And Health Policy
Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis2023Thoracic Cancer
Comparative Efficacy of ALK Inhibitors for Treatment-Naive ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis2023International Journal Of Molecular Sciences
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis2023Cancer
Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis2022Frontiers In Oncology
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis2022Bmj Open
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer2022Frontiers In Oncology
Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis2022Frontiers In Pharmacology
A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer2022Diagnostics (Basel, Switzerland)
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis2022Investigational New Drugs
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer2022The Cochrane Database Of Systematic Reviews
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis2021Frontiers In Oncology
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis2021Journal Of Clinical Medicine
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis2021Lung Cancer (Amsterdam, Netherlands)
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis2021Cancers
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis2021Oncology And Therapy
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naive ALK-Positive Lung Cancer2021Cancers
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis2020Targeted Oncology
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer2020Journal Of Comparative Effectiveness Research
Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis2020Journal Of Clinical Pharmacy And Therapeutics
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis2020Cancers
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis2020Plos One

Clinical Practice Guidelines